New hope for stubborn warts: extended treatment shows promise

NCT ID NCT07457918

Recruiting now Disease control Sponsor: Verrica Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This study follows people who already took part in earlier trials for common warts. They can receive up to 4 more treatments with YCANTH, a liquid applied to each wart every 21 days. The goal is to see if the treatment is safe and can clear all warts over about a year. Around 600 adults and children may join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS (HPV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Florida Center for Dermatology, P.A.
RECRUITING

Saint Augustine, Florida, 32080, United States
Optima Research Boardman
RECRUITING

Boardman, Ohio, 44512, United States
Texas Dermatology
RECRUITING

San Antonio, Texas, 78235, United States
The Indiana Clinical Trials Center, PC
RECRUITING

Plainfield, Indiana, 46168, United States

Conditions

Explore the condition pages connected to this study.

COMMON WARTS COMMON WARTS (VERRUCA VULGARIS) HUMAN PAPILLOMA VIRUS (HPV) WARTS